Profound Medical (TSE:PRN) Stock Crosses Above 50-Day Moving Average – Should You Sell?

Profound Medical Corp. (TSE:PRN)’s stock price passed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of C$8.73 and traded as high as C$9.18. Profound Medical shares last traded at C$9.18, with a volume of 25,086 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Raymond James Financial upgraded Profound Medical from a “moderate buy” rating to a “strong-buy” rating in a report on Monday, July 27th. Three analysts have rated the stock with a Buy rating, seventeen have given a Moderate Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Profound Medical has a consensus rating of “Moderate Buy” and an average target price of C$9.18.

Profound Medical Stock Up 11.8%

The company has a debt-to-equity ratio of 14.82, a quick ratio of 14.98 and a current ratio of 6.46. The firm’s fifty day simple moving average is C$8.73 and its 200 day simple moving average is C$9.28. The stock has a market capitalization of C$335.44 million, a price-to-earnings ratio of -9.27 and a beta of 1.50.

Profound Medical (TSE:PRN) last released its quarterly earnings results on Thursday, August 6th. The company reported C($0.37) earnings per share for the quarter. The company had revenue of C$3.53 million during the quarter. Profound Medical had a negative net margin of 170.92% and a negative return on equity of 62.45%. On average, sell-side analysts forecast that Profound Medical Corp. will post -1.90 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Thomas Michael Tamberrino bought 3,755 shares of Profound Medical stock in a transaction that occurred on Monday, August 17th. The stock was purchased at an average cost of C$9.44 per share, with a total value of C$35,447.20. Following the purchase, the insider owned 53,573 shares in the company, valued at approximately C$505,729.12. This trade represents a 7.54% increase in their ownership of the stock. Also, insider Richard Ringler Fabian bought 10,000 shares of Profound Medical stock in a transaction that occurred on Thursday, September 17th. The stock was bought at an average cost of C$8.31 per share, with a total value of C$83,100.00. Following the completion of the purchase, the insider owned 10,000 shares in the company, valued at approximately C$83,100. This trade represents a ? increase in their position. Company insiders own 8.62% of the company’s stock.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.